Clinical Trials Browser

NCT07409272 2026-04-16

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Phase 3 Recruiting

614 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06205485 2026-04-14

NEO-RT

Phase 3 Recruiting

250 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06662786 2026-04-13

OrigAMI-2

Phase 3 Recruiting

1,000 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06997497 2026-04-13

KANDLELIT-012

Phase 3 Recruiting

477 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

2,130 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06764875 2026-04-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

840 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT07265674 2026-04-09

Beacon-BTC

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06958328 2026-04-08

LAP100

Phase 3 Recruiting

356 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05253651 2026-04-07

MOUNTAINEER-03

Phase 3 Recruiting

400 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05677490 2026-04-07

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Phase 3 Recruiting

382 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07228832 2026-04-06

HARMONi-GI3

Phase 3 Recruiting

600 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03801876 2026-04-03

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Phase 3 Recruiting

300 enrolled

Gastrointestinal

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT06901531 2026-04-03

LUCERNA

Phase 3 Recruiting

500 enrolled

Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT07409428 2026-04-01

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Phase 3 Recruiting

240 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05863195 2026-03-23

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 Recruiting

408 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

Phase 3 Recruiting

100 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04230187 2026-03-05

TRIBE-C

Phase 3 Recruiting

528 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06951503 2026-03-04

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Phase 3 Recruiting

560 enrolled

Gastrointestinal

Colorectal Adenocarcinoma

NCT04215731 2026-03-03

FOBEAR

Phase 3 Recruiting

582 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

550 enrolled

Gastrointestinal

Stomach Neoplasms

NCT07389265 2026-02-05

CAPRI-3 GOIM

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Phase 3 Recruiting

550 enrolled

Gastrointestinal

Rectal Neoplasms

NCT07366528 2026-01-26

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Phase 3 Recruiting

387 enrolled

Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

555 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05008809 2025-12-12

AIO-KRK-0418

Phase 3 Recruiting

507 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07238283 2025-12-09

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

Phase 3 Recruiting

662 enrolled

Gastrointestinal

First-line Treatment of Metastatic Pancreatic Cancer

NCT06733038 2025-12-08

AtezoTRIBE2

Phase 3 Recruiting

238 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06929624 2025-11-18

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

280 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06490536 2025-08-29

The Sagittarius Trial

Phase 3 Recruiting

700 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06793917 2025-07-20

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Phase 3 Recruiting

269 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02885753 2025-07-09

OSCAR

Phase 3 Recruiting

348 enrolled

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

170 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04861558 2025-05-30

EFFIPEC

Phase 3 Recruiting

213 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06897644 2025-05-25

PANThEON

Phase 3 Recruiting

340 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT05624138 2025-05-11

The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy

Phase 3 Recruiting

64 enrolled

Neuritis

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04460352 2025-03-06

NEEDS

Phase 3 Recruiting

1,020 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Recruiting

416 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04447352 2024-11-12

PREVENT

Phase 3 Recruiting

200 enrolled

Gastrointestinal

Stomach Neoplasms

NCT04927780 2024-08-28

PREOPANC-3

Phase 3 Recruiting

378 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06041477 2024-08-27

HAIC

Phase 3 Recruiting

540 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05954078 2024-05-20

Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

Phase 3 Recruiting

340 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05751850 2024-05-09

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Phase 3 Recruiting

778 enrolled

Gastrointestinal

First-line Treatment of Advanced Pancreatic Cancer

NCT01935778 2024-02-28

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Phase 3 Recruiting

286 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06177041 2024-02-28

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 3 Recruiting

486 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT06201065 2024-01-11

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Phase 3 Recruiting

200 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT06017583 2023-10-11

Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

Phase 3 Recruiting

48 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05264896 2023-09-07

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Phase 3 Recruiting

110 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05236972 2022-12-30

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Phase 3 Recruiting

323 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05201430 2022-03-04

RCNAC

Phase 3 Recruiting

300 enrolled

Gastrointestinal

Rectal Neoplasms